In this video, Sanjal Desai, MBBS, Mayo Clinic, Rochester, MN, discusses the association of interim PET2 response with outcomes in patients with diffuse large B-cell lymphoma (DLBCL) treated with two R-CHOP-based regimens. Dr Desai first discusses the patient cohorts analyzed in this study, and then highlights some results which provide strong evidence for the ability of PET2 response to predict early outcomes and select high-risk patient populations. To conclude, Dr Desai highlights the importance of using PET2 in the future to analyze other modalities. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.